Boston Scientific
BSX
$41.98
-2.35%
Boston Scientific is a global medical technology company that develops minimally invasive devices delivered into the body through small incisions or natural openings, spanning interventional cardiology, cardiac rhythm management, electrophysiology, endoscopy, urology, neuromodulation, and peripheral interventions, with roughly 36% of sales generated outside the United States. It operates as a scaled, diversified device platform competing against Medtronic, Abbott, Edwards Lifesciences, and Stryker, distinguished by its fast-growing electrophysiology (Farapulse) franchise, its Watchman left atrial appendage closure business, and an aggressive tuck-in M&A strategy that has repeatedly moved it into adjacent high-growth markets. The current investor narrative has turned sharply negative: a cybersecurity disruption forced management to cut fourth-quarter sales and full-year EPS guidance on the October 28 print, sending shares down 6% and prompting a Zacks "Bear of the Day" flag, while bulls counter that the setback is temporary, that the pipeline and cost discipline remain intact, and that a $1.5 billion MiRus TAVR investment plus potential Penumbra acquisition optionality are being ignored at 13x forward earnings. The debate is now squarely about whether this is a transient operational hiccup inside a durable double-digit medtech compounder or the start of a multi-year growth stall through 2027.…
BSX
Boston Scientific
$41.98
Related headlines
Investment Opinion: Should I buy BSX Today?
Rating: Hold with a constructive lean. The core thesis is that BSX is a scaled, cash-generative medtech compounder trading at a deeply de-rated 14.16x forward EPS of $4.008, but the earnings base underpinning that multiple was just cut on the October 28 cyber-related guidance reduction, and Q3 revenue growth of only 1.44% YoY gives no confirmation yet that the trough has passed. The analyst consensus of "buy" (recommendation mean 1.935 across 28 analysts, 19 Buy / 12 Hold / 0 Sell) and an average target of $49.60 imply +11.9% upside from $44.34, which is a positive but not compelling risk/reward given the 46% spread between the $41.00 low and $60.00 high targets.
Supporting evidence is genuinely mixed but tilts modestly positive on valuation. The forward PE of 14.16x compares with a trailing PE of 48.65x and historical PE readings of 47.86x–52.97x through 2025, while PS of 7.03x sits roughly 75% below the 26.75x–31.38x range of the prior year — the stock is at the bottom of its multi-year valuation band. Gross margin of 69.01% and operating margin of 19.78% remain competitive for medical devices, trailing free cash flow of $3.331 billion equals about 2.4% of the $141.2 billion market cap, and the PEG of 0.876 signals cheapness relative to expected growth if estimates hold. Against that, revenue decelerated from +11.6% in Q1 to +7.5% in Q2 to +1.44% in Q3, gross margin fell roughly 400bp sequentially to 66.72%, and quarterly free cash flow dropped to $868 million from $1.279 billion.
The biggest risks that could invalidate the thesis are (1) the cyber remediation dragging into 2027 so that 1.44% growth becomes the new baseline rather than a trough, (2) further downward EPS revisions from the $4.008 consensus toward the $3.93 low end or below, and (3) continued margin compression from unfavorable mix and under-absorbed manufacturing costs. This Hold would upgrade to Buy if Q4 revenue growth reaccelerates back above mid-single digits and gross margin recovers toward the 69–70% level, or if the stock pulls back toward the $41.00 analyst low target while estimates stabilize; it would downgrade to Sell on a decisive break below the $39.57 52-week low accompanied by another guidance cut. On balance the stock looks undervalued relative to its own history but only fairly valued relative to a still-unproven recovery — a value opportunity contingent on execution, not a confirmed bargain.
Sign up to view all
BSX 12-Month Price Forecast
BSX presents a genuinely two-sided setup: the valuation is at the bottom of its multi-year band on both earnings and sales multiples, the Street has zero Sell ratings and a positive average target, and cash generation of $3.331 billion TTM funds both M&A and buybacks — yet the growth and margin data are deteriorating, with Q3 revenue up only 1.44% and gross margin down roughly 400bp sequentially. The 14.16x forward multiple is only cheap if the $4.008 EPS estimate holds, and management just cut guidance, so the market is correctly withholding a re-rating until evidence arrives. The wide $41.00–$60.00 target range and the 46% spread reflect real uncertainty about whether this is a transient cyber-driven trough or the start of a multi-year stall through 2027. I would upgrade to bullish on a Q4 print showing revenue growth back above 5% with gross margin recovering toward 69%, and downgrade to bearish on a break below the $39.57 52-week low or a cut to forward EPS below $3.93. Until one of those resolves, the risk/reward is asymmetric but unconfirmed, warranting a neutral stance with patience over conviction.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Boston Scientific's 12-month outlook, with a consensus price target around $49.60 and implied upside of +18.1% versus the current price.
Average Target
$49.60
31 analysts
Implied Upside
+18.1%
vs. current price
Analyst Count
31
covering this stock
Price Range
$41 - $60
Analyst target range
Coverage is deep and still leans bullish despite the wreckage: 28 analysts with 19 Buy, 12 Hold, and 0 Sell ratings, a consensus recommendation of "buy" and a recommendation mean of 1.935 (where 1.0 is a strong buy). The average target price of $49.60 implies +11.9% upside from the $44.34 current price, a modest but positive signal, and the consensus is best characterized as cautiously bullish — the complete absence of Sell ratings alongside 12 Holds suggests analysts see the downside as largely priced in but are unwilling to pound the table until guidance stabilizes. Forward EPS estimates of $4.008 (range $3.934–$4.228) and revenue estimates of $25.57 billion underpin that constructive stance.
The target range of $41.00 to $60.00 is wide — a 46% spread from low to high — signaling genuine uncertainty about the duration of the disruption. The $60 high target assumes the cyber issue is fully transient, growth reaccelerates toward double digits, and the MiRus TAVR and potential Penumbra acquisition add multiple expansion; the $41 low target, just 7.5% below the current price, essentially prices in continued margin compression and a growth stall through 2027. Institutional ratings show a clear negative drift around the October 28–30 guidance cut: TD Cowen downgraded to Hold from Buy and Jefferies moved to Hold from Buy, while UBS, RBC, Bernstein, Leerink, and Canaccord Genuity maintained Buy/Outperform and Citigroup, Barclays, and Wells Fargo stayed Neutral. The pattern of two downgrades to Hold with no upgrades confirms the Street is in wait-and-see mode, and the tight low end of the range near the current price suggests limited perceived downside but equally limited near-term conviction on the upside.
Bulls vs Bears: BSX Investment Factors
The bear case currently carries stronger near-term evidence: revenue growth of 1.44%, a 400bp sequential gross margin decline, two analyst downgrades to Hold, and a -57.76% one-year collapse are concrete and recent, whereas the bull case rests on a forward EPS estimate that management just cut and a valuation argument that has been early for twelve months. That said, the bear evidence is largely about a single disruption event, while the bull evidence — 14.16x forward earnings, a 0.876 PEG, $3.33 billion of trailing FCF, and zero Sell ratings — speaks to what survives if the disruption proves transient. The single most important tension is whether Q3's 1.4% growth is a cyber-driven trough or the start of a multi-year stall through 2027; that one question determines whether 14x forward earnings is a generational entry point or a value trap. Until management demonstrates a return to mid-single-digit growth, the risk/reward is asymmetric but unconfirmed, favoring patience over conviction.
Bullish
- Forward PE of 14.2x is deeply discounted: At $44.34, BSX trades at 14.16x forward EPS of $4.008 versus a trailing PE of 48.65x, a 71% compression that implies the market expects earnings to roughly triple off a disruption-depressed base. The PEG ratio of 0.876 signals the stock is cheap relative to expected growth if estimates hold, and the forward multiple is unusually low for a scaled medtech franchise with a 69.0% gross margin.
- Analyst consensus still leans Buy with no Sells: Of 28 analysts, 19 rate Buy, 12 Hold, and zero Sell, with a recommendation mean of 1.935 and an average target of $49.60 implying +11.9% upside from $44.34. The complete absence of Sell ratings alongside a low target of $41.00 (only 7.5% below the current price) suggests the Street sees downside as largely priced in.
- Valuation at multi-year lows on sales: Current PS of 7.03x and EV/Sales of 3.6x compare with historical PS ratios of 26.75x in Q4 2025, 28.56x in Q3 2025, and 31.38x in Q2 2025 — a roughly 75% de-rating on sales multiples. The stock sits at the very bottom of its multi-year valuation band, which historically has marked accumulation zones for durable compounders.
- Cash generation and balance sheet remain solid: Trailing free cash flow of $3.331 billion yields about 2.4% of the $141.2 billion market cap, and debt-to-equity of 0.512 with a current ratio of 1.617 shows moderate leverage and adequate liquidity. The company funded $2.0 billion of buybacks in Q2 plus $212 million of Q3 acquisitions and a $672 million debt repayment internally, demonstrating self-funding capacity through the disruption.
Bearish
- Revenue growth collapsed to 1.44% YoY: Q3 2026 revenue of $5.138 billion grew only 1.44% versus $5.065 billion a year earlier, a sharp deceleration from +7.5% in Q2 ($5.442 billion) and +11.6% in Q1 ($5.203 billion). The sequential decline and low-single-digit growth directly validate management's guidance cut and raise the question of whether 1.4% is a trough or a new baseline.
- Margins compressing across the board: Q3 gross margin fell to 66.72% from 70.71% in Q2 and 69.44% in Q1, while operating margin dropped to 19.05% from 21.65% and net margin fell to 11.25% from 16.67%. The roughly 400bp sequential gross margin decline points to unfavorable mix and under-absorbed manufacturing costs from the cyber disruption.
- Stock in a severe, idiosyncratic downtrend: BSX is down 57.76% over the trailing year and 53.18% YTD, with a max drawdown of -60.39% and -70.03% one-year relative strength versus SPY's +12.27% gain. At $44.34 the stock sits at just 7.5% of its 52-week range ($39.57–$102.71), and the divergence from a beta of 0.585 confirms company-specific risk rather than market correlation.
- Street downgrades signal wait-and-see: TD Cowen and Jefferies both downgraded to Hold from Buy around the October 28 guidance cut, with no offsetting upgrades, while Citigroup, Barclays, and Wells Fargo stayed Neutral. The $41.00–$60.00 target range is a 46% spread that signals genuine uncertainty about how long the disruption lasts, and Zacks flagged BSX as its "Bear of the Day."
BSX Technical Analysis
The prevailing trend is unambiguously broken: BSX is down 57.76% over the trailing year and 53.18% year-to-date, a collapse that has erased more than half the equity value and produced a max drawdown of -60.39%. At $44.34, the stock sits at just 7.5% of its 52-week range (low $39.57, high $102.71), meaning it is pinned near the bottom of the band rather than consolidating mid-range — a positioning that historically signals either capitulation-style value or a falling knife, and the -70.03% one-year relative strength versus SPY confirms severe, persistent underperformance rather than a brief air pocket. The gap between the $102.71 high and the current price implies the market has fully repriced the growth story, so any stabilization must be earned through evidence, not mean reversion alone.
Short-term momentum, however, is diverging constructively from the long-term wreckage. The stock is up 3.12% over the past month versus a -2.26% decline for SPY, producing +5.38% relative strength, and the last six weeks show a clear higher-low sequence from the $41.58 October 7 low to the $45.82 November 4 high before a pullback to $44.34. That said, the 3-month change of -14.45% and 6-month change of -15.83% show the bounce is occurring inside a still-declining intermediate trend, and the 1-month outperformance is too small in absolute terms to call a reversal — it reads as stabilization and short-covering after the guidance cut rather than accumulation. With volume data unavailable (reported as 0) and no RSI provided, the quality of the rally cannot be confirmed, which argues for treating the recent strength as tentative.
Key levels are well defined by the 52-week envelope: support sits at the $39.57 low, roughly 10.8% below the current $44.34, and a decisive break there would confirm the downtrend and likely trigger another leg of momentum-driven selling. Resistance is the $102.71 high, but the actionable near-term ceiling is the $45.82 November 4 swing high and the $49.60 consensus target area; reclaiming those would signal the market is beginning to price recovery. Volatility context matters enormously here: beta of 0.585 implies the stock should move roughly 42% less than SPY, yet it has delivered a -60.39% drawdown against a +12.27% one-year SPY gain — the divergence is idiosyncratic, company-specific risk, not market beta, so position sizing should be driven by event risk (guidance credibility, cyber remediation) rather than index correlation.
Beta
0.58
0.58x market volatility
Max Drawdown
-60.4%
Largest decline past year
52-Week Range
$40-$102
Price range past year
Annual Return
-56.5%
Cumulative gain past year
| Period | BSX Return | S&P 500 |
|---|---|---|
| 1m | -5.7% | -9.7% |
| 3m | -16.7% | -9.9% |
| 6m | -27.3% | -7.5% |
| 1y | -56.5% | +4.7% |
| ytd | -55.7% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BSX Fundamental Analysis
The revenue trajectory has decelerated to a crawl: Q3 2026 revenue of $5.138 billion grew only 1.44% year-over-year against $5.065 billion in Q3 2025, a stark slowdown from the $5.442 billion (+7.5% YoY) posted in Q2 2026 and the $5.203 billion (+11.6% YoY) in Q1 2026. The sequential decline from Q2 to Q3 and the collapse in YoY growth to low single digits is the clearest evidence that the cybersecurity disruption hit shipments and procedure volumes, and it directly validates management's guidance cut. Segment mix shows Cardiovascular at $3.406 billion and MedSurg at $1.733 billion, with the larger cardiovascular franchise (roughly two-thirds of sales) carrying the growth burden — any electrophysiology or Watchman softness is therefore disproportionately damaging. The investment case now hinges on whether 1.4% growth is a trough quarter or a new baseline, and the analyst revenue consensus of $25.57 billion for the forward year implies the Street expects a return to mid-single-digit growth.
Profitability remains solid but is compressing at the margin. Q3 2026 net income was $578 million on a 66.72% gross margin, down from $907 million and 70.71% in Q2 2026 and $1.337 billion and 69.44% in Q1 2026 — a clear deterioration in both dollars and margin percentage. The Q3 operating margin of 19.05% compares unfavorably to 21.65% in Q2 and 20.60% in Q1, and the 11.25% net margin is the weakest of the last four quarters versus 16.67% in Q2 and 25.70% in Q1 (the latter flattered by a tax benefit). Gross margin of 66.72% is consistent with premium medtech device economics, but the 400bp sequential decline suggests unfavorable mix and under-absorbed manufacturing costs from the disruption. Trailing EPS of $0.02 versus forward estimates near $4.01 underscores how depressed the current earnings base is relative to normalized expectations.
The balance sheet is sound but cash generation has become lumpy. Debt-to-equity of 0.512 and a current ratio of 1.617 indicate moderate leverage and adequate liquidity, while trailing free cash flow of $3.331 billion against a $141.2 billion market cap yields roughly 2.4% — respectable but not cheap for a decelerating grower. Quarterly FCF swung from $1.279 billion in Q2 to $868 million in Q3 as operating cash flow fell to $1.048 billion from $1.474 billion, and the company repurchased $2.0 billion of stock in Q2 while also deploying $212 million on acquisitions in Q3 and $523 million in Q1. ROE of 11.91% and ROA of 5.87% are below the company's historical medtech peer standards, reflecting the earnings compression. The company can fund itself internally, but the combination of M&A spend, buybacks, and a $672 million Q3 debt repayment leaves less cushion if the disruption persists into 2027.
Quarterly Revenue
$5.1B
2026-09
Revenue YoY Growth
+1.4%
YoY Comparison
Gross Margin
66.7%
Latest Quarter
Free Cash Flow
$3.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BSX Overvalued?
Because net income is positive ($578 million in Q3, $3.331 billion FCF TTM), the PE ratio is the appropriate primary metric, and the dispersion between trailing and forward is the entire story: trailing PE of 48.65x versus forward PE of 14.16x. That 71% compression implies the market expects earnings to roughly triple, consistent with forward EPS estimates of $4.008 against trailing EPS of $0.02 — a gap that reflects a depressed, disruption-distorted trailing base rather than genuine hyper-growth. The forward multiple of 14.16x is remarkably low for a scaled medtech franchise, and the PEG ratio of 0.876 suggests the stock is cheap relative to expected growth if those estimates hold.
Against its own sector, the stock screens cheap on most measures: PS of 7.03x, EV/Sales of 3.6x, and EV/EBITDA of 29.70x, with a 69.01% gross margin and 19.78% operating margin that are competitive for medical devices. The 5.82x price-to-book is elevated in absolute terms but reflects a premium franchise with intangible-heavy assets. The critical caveat is that the forward PE of 14.16x and PEG of 0.876 are only cheap if the $4.01 EPS estimate is achievable — the guidance cut and 1.44% revenue growth put that assumption under active review, and the 31.13x price-to-cash-flow ratio shows the market is not yet pricing a full recovery.
Historically, BSX has traded at far richer multiples: the historical ratio series shows PE of 52.97x in Q4 2025, 47.86x in Q3 2025, and 49.73x in Q2 2025, with PS ratios of 26.75x, 28.56x, and 31.38x respectively. The current PS of 7.03x and trailing PE of 48.65x sit at the very bottom of the company's multi-year valuation band, a de-rating of roughly 75% on sales multiples. That places the stock near historical lows — which can mean either a genuine value opportunity or that the market is pricing fundamental deterioration, and the 1.44% growth print tilts the evidence toward the latter until proven otherwise.
PE
48.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 17x~87x
vs. Industry Avg
26.4x
Industry PE ~26.4x*
EV/EBITDA
29.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the earnings base and cash flow quality. Trailing EPS of $0.02 against a $4.008 forward estimate means the entire valuation case depends on a near-tripling of earnings that management just guided down, and Q3 net income of $578 million fell from $907 million in Q2 and $1.337 billion in Q1. Gross margin compressed to 66.72% from 70.71% sequentially while operating margin fell to 19.05% from 21.65%, and quarterly free cash flow dropped to $868 million from $1.279 billion as operating cash flow fell to $1.048 billion. With $2.0 billion of Q2 buybacks, $212 million of Q3 acquisitions, and a $672 million debt repayment already absorbed, the cushion to keep funding M&A and returns shrinks if the disruption persists into 2027. Revenue concentration adds to the risk: Cardiovascular at $3.406 billion is roughly two-thirds of sales, so any electrophysiology or Watchman softness is disproportionately damaging.
Market and competitive risks are dominated by valuation compression and event risk rather than beta. A beta of 0.585 implies BSX should move roughly 42% less than SPY, yet it has delivered a -60.39% max drawdown against SPY's +12.27% one-year gain — the damage is idiosyncratic, so index correlation offers no protection. The stock has already de-rated roughly 75% on sales multiples (PS of 7.03x versus 26.75x–31.38x through 2025), meaning further compression would require a genuine fundamental deterioration rather than sentiment alone. Competitive pressure from Medtronic, Abbott, Edwards Lifesciences, and Stryker in electrophysiology and TAVR is intensifying just as BSX commits $1.5 billion to MiRus, and the Zacks "Bear of the Day" flag plus two downgrades to Hold raise the risk of further negative sell-side revisions if Q4 disappoints.
The worst-case scenario is a chain in which the cyber remediation drags into 2027, Q4 revenue fails to reaccelerate from 1.44% growth, forward EPS estimates of $4.008 are cut toward the $3.93 low end or below, and the 14.16x forward multiple proves to be a value trap rather than a discount. In that path, the stock retests its 52-week low of $39.57 — about 10.8% below the current $44.34 — and a decisive break there would likely trigger momentum-driven selling toward the $41.00 analyst low target and beyond, with the -60.39% historical max drawdown as the outer bound. Realistically, an investor could lose roughly 11% to the 52-week low and up to 20–25% in a full re-rating scenario where estimates reset lower and the multiple stays compressed.
FAQ
The most severe risk is company-specific execution: the cyber remediation could drag into 2027, keeping revenue growth near the 1.44% Q3 level and forcing forward EPS below the $3.93 low end, which would turn the 14.16x multiple into a value trap. Second is margin deterioration — gross margin already fell roughly 400bp sequentially to 66.72% and operating margin to 19.05%, and continued mix-driven compression would erode the earnings base further. Third is financial/cash-flow risk: quarterly free cash flow dropped to $868 million from $1.279 billion even as the company absorbed $2.0 billion of Q2 buybacks and $212 million of Q3 acquisitions, leaving less cushion if the disruption persists. Fourth is competitive and sentiment risk — pressure from Medtronic, Abbott, Edwards, and Stryker in electrophysiology and TAVR, plus two October downgrades to Hold and a Zacks "Bear of the Day" flag, could trigger further negative revisions. Ranked by severity: execution/guidance credibility first, margin compression second, cash flow third, competitive and sentiment risk fourth.
The 12-month outlook splits into three scenarios. The base case (55% probability, $46–$52) assumes growth stabilizes in the low-to-mid single digits, forward EPS of $4.008 holds, and the stock grinds toward the $49.60 analyst average. The bull case (25% probability, $55–$60) requires Q4 revenue growth reaccelerating above 5% with gross margin recovering toward 69–70%, a multiple re-rating toward the high-teens to low-20s, and MiRus/Penumbra optionality, carrying shares toward the $60 high target. The bear case (20% probability, $39.57–$41.00) assumes remediation drags into 2027, EPS is cut below $3.93, and the stock retests its 52-week low. The base case is most likely, and its key assumption is that the cyber disruption proves transient and the $4.008 EPS estimate holds — the wide $41–$60 range reflects genuine uncertainty on that single question.
On most measures BSX screens undervalued relative to its own history. The forward PE of 14.16x compares with a trailing PE of 48.65x and historical readings of 47.86x–52.97x through 2025, while PS of 7.03x and EV/Sales of 3.6x sit roughly 75% below the 26.75x–31.38x sales multiples of the prior year. The PEG of 0.876 and EV/EBITDA of 29.70x round out a picture of a stock at the bottom of its multi-year band. The market is effectively pricing in a permanent growth stall rather than a temporary operational hiccup, which is why the forward multiple is so compressed. The catch is that this cheapness is conditional: it only holds if the $4.008 forward EPS estimate survives, and management just cut guidance. Relative to peers the 69.01% gross margin and 19.78% operating margin remain competitive, so the discount reflects event risk rather than franchise deterioration — fairly valued relative to an unproven recovery, undervalued relative to history.
From a risk/reward standpoint, BSX offers a modestly favorable but unconfirmed setup: the $49.60 average analyst target implies +11.9% upside from $44.34, and the $41.00 low target sits only 7.5% below the current price, suggesting the Street sees limited further downside. The valuation is genuinely cheap at 14.16x forward EPS of $4.008 with a 0.876 PEG, and 19 of 28 analysts rate it Buy with zero Sells. But the biggest downside risk is real — a retest of the $39.57 52-week low is about 10.8% below the current price, and a full re-rating could cost 20–25%. It is a good buy primarily for patient investors who believe the cyber disruption is transient and who can tolerate a 12–24 month wait for evidence; it is not a good buy for anyone needing near-term momentum or income, given the 0% dividend yield and -57.76% one-year decline.
BSX is better suited to long-term holding than short-term trading. It is a mature, scaled medtech compounder with $3.331 billion trailing FCF, a 69.0% gross margin, and a diversified cardiovascular and MedSurg portfolio, but its earnings visibility is currently poor — revenue growth collapsed to 1.44% and guidance was cut on October 28. The beta of 0.585 implies low market correlation, yet the stock delivered a -60.39% max drawdown against SPY's +12.27% one-year gain, meaning the volatility is idiosyncratic event risk rather than tradable market beta. With a 0% dividend yield and no income support, short-term traders face headline-driven gap risk around the Q4 print. A concrete suggested minimum holding period is 12–24 months, long enough for the cyber drag to fade, gross margin to recover toward 69–70%, and the multiple to re-rate if the recovery materializes.

